WealthCare Investment Partners’s Capital Group Dividend Value ETF CGDV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Buy
246,289
+76,604
+45% +$3.4M 2.95% 5
2025
Q4
$7.46M Buy
169,685
+64,921
+62% +$2.79M 2.17% 9
2025
Q3
$4.43M Buy
104,764
+23,939
+30% +$984K 1.44% 17
2025
Q2
$3.25M Buy
80,825
+17,417
+27% +$631K 1.17% 22
2025
Q1
$2.08M Buy
63,408
+11,116
+21% +$404K 0.88% 34
2024
Q4
$1.84M Buy
52,292
+270
+0.5% +$9.82K 0.8% 33
2024
Q3
$1.89M Buy
52,022
+914
+2% +$31.7K 0.83% 34
2024
Q2
$1.69M Buy
51,108
+1,005
+2% +$32.7K 0.78% 32
2024
Q1
$1.63M Sell
50,103
-200
-0.4% -$6.15K 0.79% 34
2023
Q4
$1.5M Buy
50,303
+18,806
+60% +$519K 0.82% 34
2023
Q3
$828K Hold
31,497
0.5% 50
2023
Q2
$848K Sell
31,497
-28
-0.1% -$719 0.51% 51
2023
Q1
$786K Buy
+31,525
New +$771K 0.48% 56

Other funds holding CGDV

WealthCare Investment Partners's CGDV Position: Q1 2026 in Review

WealthCare Investment Partners increased its Capital Group Dividend Value ETF (CGDV) stake by 45% in Q1 2026, buying an estimated $3.4M and bringing the position to 246,289 shares worth $10.6M. The position accounts for 2.95% of the portfolio, ranked #5.

WealthCare Investment Partners first reported a position in CGDV in Q1 2023 and has held it in 13 quarters since. 730 funds tracked by Wall St. Rank hold CGDV as of Q1 2026.

  • WealthCare Investment Partners held 246,289 shares of Capital Group Dividend Value ETF worth $10.6M as of Q1 2026.
  • WealthCare Investment Partners bought 76,604 Capital Group Dividend Value ETF shares in Q1 2026, an estimated $3.4M.
  • Capital Group Dividend Value ETF made up 2.95% of WealthCare Investment Partners's portfolio in Q1 2026, its #5 holding.
  • WealthCare Investment Partners first reported a position in Capital Group Dividend Value ETF in Q1 2023 and has held it in 13 quarters since.
  • 730 funds tracked by Wall St. Rank held Capital Group Dividend Value ETF as of Q1 2026.

Based on WealthCare Investment Partners's 13F filing for Q1 2026, filed 9 Apr 2026.